Hone Health

The waiting room moved into your kitchen

A 44-year-old in Ohio spits into a tube, taps an app, and three days later a doctor he has never met in person explains why he has felt like a phone at 8% battery for two years. No clipboard. No fluorescent lobby. No nurse calling a name into a crowd. This is a routine Tuesday at Hone Health, and it is happening roughly 55,000 times over.

Hone is a telemedicine clinic for the unglamorous middle of adult health - the hormones, the metabolism, the slow leaks that don't show up as an emergency but quietly rewrite a decade. It tests more than 40 biomarkers, hands the results to a licensed physician, and builds a plan you can actually follow from home. By September 2025 that approach was running at $113.5 million in annual recurring revenue. Not bad for a company whose entire pitch is, essentially, "your doctor was wrong to tell you it was nothing."

Healthcare is great at emergencies, terrible at slopes

The American system is engineered to catch the cliff - the heart attack, the tumor, the break. It is far less interested in the slope that leads there: the testosterone that drifts down, the thyroid that drifts up, the metabolic markers that creep for years while everyone agrees you look "fine." A standard physical checks a handful of numbers. Hone checks more than forty.

There is a market-sized irony here. Tens of millions of Americans between 35 and 55 feel measurably worse than they used to and get told, with great warmth, that nothing is wrong. They are not hypochondriacs. They are under-measured. Hone put a number on the gap: roughly 40 million people in that band, most of whom have never had their hormones properly mapped.

The skeptic's question is fair: isn't this just selling worried-well adults expensive tests they don't need? Hone's answer is to lead with data, not vibes - measure first, prescribe second, and keep measuring. The retention numbers suggest people stick around because something changed, not because the marketing was clever.

It started with one founder feeling terrible

At 35, co-founder and CEO Saad Alam was exhausted, gaining weight, foggy, and struggling in ways his doctor waved off as ordinary aging. He spent six months and a small fortune consulting specialists before he found real answers. The experience left him with a conviction and a grudge: the information existed, but ordinary people had no clean path to it.

He also had a more personal stake. Alam has spoken about watching chronic disease take his father - conditions, he argues, that were largely preventable. Hone is in many ways an attempt to give other families a different ending.

In 2018, Alam teamed with Stuart Blitz, Matt Buckleman and Alba Mertira to build the thing he had wished existed. The bet was simple to state and hard to execute: package elite, specialist-grade hormone care into a subscription a normal person could afford and run from their couch.

Measure, prescribe, then keep measuring

Hone's loop is deceptively boring, which is the point. You test - at home or in person - across 40+ biomarkers. A physician reads the results and builds a plan. Medication, if prescribed, ships to your door. Then you test again, because hormones are a moving target and a one-time snapshot is mostly decoration.

The pricing is built to be legible rather than mysterious. Membership runs roughly $129 to $149 a month, bundling the testing, the doctor and the prescriptions; the average member spends about $225 a month all in. That is not cheap, and Hone doesn't pretend otherwise - it sits at the premium end of a market that runs from $99 mail-order testosterone to traditional clinics. What members are buying is less a product than a standing relationship with their own data.

The numbers that make investors lean in

Wellness companies are easy to start and hard to keep. Customers try, feel little, and drift. Hone's defense is its retention - reportedly two to three times higher than comparable direct-to-consumer health companies, with payback periods about half as long. Translation: when people start feeling better, they stay.

There is also the matter of who wrote the checks. The $33M Series A was led by Tribe Capital, with participation from Saudi Arabia's Public Investment Fund, Republic Capital, FJ Labs and others. The angel list reads like a podcast feed: Codie Sanchez, Anthony Pompliano, and the founders of Morning Brew, The Hustle and the Premier Lacrosse League. Same month, Hone acquired ivee - so a nurse can now show up at your door, not just a package.

Aging, treated as a set of problems - not a verdict

Hone's stated mission is to help aging Americans live better, healthier lives through proactive, personalized care delivered "with unexpected convenience and humanity." Underneath the corporate phrasing is a sharper idea: a lot of what we file under "getting old" is actually a list of measurable, treatable variables nobody bothered to measure.

The company runs on five house values - Compassionate Precision, Empathetic Expertise, Proactive Progress, Informed Clarity, and Sophisticated Ingenuity. The throughline is honesty: tell people what their numbers say, in language they understand, and let them decide. It is a refreshing pitch in a category that often prefers mystery and monthly billing.

The competition is fierce - which is the good news

Hone is not alone. Hims & Hers, Ro and Function Health are all circling the same insight from different angles, and traditional clinics aren't going quietly. Crowded markets are usually a sign the underlying need is real. The open question is who owns the long relationship - the years of testing, adjusting and re-testing - rather than the one-off prescription.

Hone's wager is that owning the data and the cadence wins. Its proprietary records now hold one of the larger longitudinal pools of hormone data anywhere, and the ivee deal means it can meet patients at the door instead of the mailbox. If the next decade of medicine is preventive rather than reactive, the company that has already measured you 40 ways has a head start.

There are real risks worth naming. Regulators watch direct-to-consumer prescribing closely, GLP-1 and hormone categories attract both demand and scrutiny, and a clinic that profits from prescriptions must keep proving it measures first and sells second. Hone's bet is that transparency - real numbers, real physicians, real follow-ups - is the durable answer to all three. The customers who keep renewing seem, so far, to agree.

Back to that 44-year-old in Ohio. A few years ago his options were a shrug and a vitamin aisle. Now he has a number, a doctor, a plan, and a follow-up on the calendar. The waiting room didn't get better. Hone just decided he didn't need one.